» Articles » PMID: 29498740

Varicella-zoster Virus Infection: Natural History, Clinical Manifestations, Immunity and Current and Future Vaccination Strategies

Overview
Journal New Microbiol
Specialty Microbiology
Date 2018 Mar 3
PMID 29498740
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Varicella-zoster virus (VZV) is the etiologic agent of varicella (chicken pox), a childhood exanthematic disease that develops as a result of primary infection, and zoster (shingles), caused by reactivation of the virus persisting in a latent form in the dorsal sensory ganglia. Although varicella is generally a mild self-limiting illness, in immunocompromised subjects and adults it can have a serious clinical course that can lead to permanent damage of the central nervous system. In these and in most zoster cases, treatment with anti-herpetic drugs and/or immunotherapy is necessary. Because it is highly contagious, varicella is one of the most common exanthematic diseases. It is preventable by vaccination with an attenuated vaccine administered around the first year of age, and with a boost vaccination in school age. This article briefly describes the natural history and pathophysiology of VZV infection and its current epidemiology and provides an overview of current and future vaccine options to protect against varicella and/or zoster.

Citing Articles

Virus-Induced Hypercoagulable State: A Mythical Cause for Cerebral Venous Sinus Thrombosis in an Adult Male.

Nanda Palanisamy N, Selvam N, Vijayan S, Ethiraju V Cureus. 2025; 17(1):e78118.

PMID: 40018474 PMC: 11866259. DOI: 10.7759/cureus.78118.


Assessing the Knowledge, Attitude, and Practice of Healthcare Workers on the Herpes Zoster Vaccine in Saudi Arabia: A Cross-Sectional Study.

Moustafa N, Alsaif N, Alsaeed E, Alanezi A, Algarni A, Alkathery L Cureus. 2025; 17(1):e77302.

PMID: 39944423 PMC: 11821283. DOI: 10.7759/cureus.77302.


Comparison of ELISA Versus FAMA Titers in Children After Chemotherapy and Hematopoietic Stem Cell Transplantation Who Received the Live Attenuated MAV/06 Strain Varicella Vaccine.

Ahn B, Kang K, Kim Y, Cho Y, Jo S, Yoo J Vaccines (Basel). 2025; 12(12.

PMID: 39772033 PMC: 11679963. DOI: 10.3390/vaccines12121371.


Seroprevalence Assessment of Anti-Varicella Antibodies among Adults in the Province of Florence (Italy).

Bechini A, Riccio M, Salvati C, Bonito B, Zanella B, Biamonte M Vaccines (Basel). 2024; 12(9).

PMID: 39340086 PMC: 11435818. DOI: 10.3390/vaccines12091056.


Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024).

Ricco M, Ferraro P, Zaffina S, Camisa V, Marchesi F, Franzoso F Vaccines (Basel). 2024; 12(9).

PMID: 39340051 PMC: 11436139. DOI: 10.3390/vaccines12091021.